{"analyses":[{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.02","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"OTHER","pValue":"0.0641","paramType":"Hazard Ratio (HR)","paramValue":"0.74","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.67","upperLimit":"6.31","value":"5.45"},{"groupId":"OG001","lowerLimit":"5.55","upperLimit":"7.39","value":"6.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"231"}],"units":"Participants"}],"description":"DOR is defined as the time period from the date of initial CR or PR until the date of PD or death from any cause, whichever occurs first. CR is defined as the disappearance of all TLs and SA reduction to \\<10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD. PD is defined as \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"Duration of response (DoR)-evaluable population: participants in the ITT population with measurable disease at baseline","reportingStatus":"POSTED","timeFrame":"From objective response to PD, assessed up to primary completion date (approximately 26 months)","title":"Duration of Objective Response (DOR) Assessed Using RECIST v1.1 in DOR-evaluable Population (Unconfirmed)","type":"SECONDARY","unitOfMeasure":"Months"}